UBS Maintains Buy on Alaska Air Group, Raises Price Target to $54
UBS analyst Atul Maheswari maintains Alaska Air Group (NYSE:ALK) with a Buy and raises the price target from $52 to $54.
Stocks · News reference
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier, U.S. FAA Says New Circuit Is Ready To Install, Should Be Operational By 1:30PM EST; Will Not Restart System For Incoming Flights At Some East Coast Airports Until Sure The Airspace Is Safe; Loss Of Communications Issue At Philadelphia Facility Prompting Significant Flight Cuts; Backup Fiber Line Was Been Accidentally Cut By Construction Crew
Reported Earlier, U.S. FAA Says Not Clear When The Ground Stops At The New York Area Airports Can Be Lifted; FAA Temporarily Halts Flights Into Newark And Philadelphia Airports Due To Communications Issues With Some Frequencies At Air Traffic Control Facility; Ground Stops At New York JFK, LaGuardia, Boston Airports
Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.
RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target
RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.